Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Harold J. Burstein, Giuseppe Curigliano, Sibylle Loibl, et al.
Annals of Oncology (2019) Vol. 30, Iss. 10, pp. 1541-1557
Open Access | Times Cited: 584

Showing 1-25 of 584 citing articles:

Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortés, Lajos Pusztai, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 9, pp. 810-821
Open Access | Times Cited: 2195
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew Tutt, Judy E. Garber, Bella Kaufman, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 25, pp. 2394-2405
Open Access | Times Cited: 1167
Breast cancer
Sibylle Loibl, Philip Poortmans, Monica Morrow, et al.
The Lancet (2021) Vol. 397, Iss. 10286, pp. 1750-1769
Closed Access | Times Cited: 1122
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf, Hong Zhang, Carlos H. Barrios, et al.
The Lancet (2020) Vol. 396, Iss. 10257, pp. 1090-1100
Closed Access | Times Cited: 851
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Harold J. Burstein, Giuseppe Curigliano, Beat Thürlimann, et al.
Annals of Oncology (2021) Vol. 32, Iss. 10, pp. 1216-1235
Open Access | Times Cited: 603
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortés, Rebecca Dent, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 6, pp. 556-567
Open Access | Times Cited: 402
Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)
Beata Smolarz, Anna Zasowska‐Nowak, Hanna Romanowicz
Cancers (2022) Vol. 14, Iss. 10, pp. 2569-2569
Open Access | Times Cited: 277
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
Amanda Kerr, David Dodwell, Paul McGale, et al.
Cancer Treatment Reviews (2022) Vol. 105, pp. 102375-102375
Open Access | Times Cited: 196
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis
Arlindo R. Ferreira, Antonio Di Meglio, Barbara Pistilli, et al.
Annals of Oncology (2019) Vol. 30, Iss. 11, pp. 1784-1795
Open Access | Times Cited: 184
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
Khalid El Bairi, Harry R. Haynes, Elizabeth F. Blackley, et al.
npj Breast Cancer (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 178
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
Maria Vittoria Dieci, Federica Miglietta, Valentina Guarneri
Cells (2021) Vol. 10, Iss. 2, pp. 223-223
Open Access | Times Cited: 177
The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition
Sherene Loi, Stefan Michiels, Sylvia Adams, et al.
Annals of Oncology (2021) Vol. 32, Iss. 10, pp. 1236-1244
Open Access | Times Cited: 170
Triple-negative breast cancer: promising prognostic biomarkers currently in development
Jasmine Sukumar, Kelly C. Gast, Dionisia Quiroga, et al.
Expert Review of Anticancer Therapy (2020) Vol. 21, Iss. 2, pp. 135-148
Open Access | Times Cited: 159
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment
Xi Wang, Shusen Wang, Heng Huang, et al.
JAMA (2020) Vol. 325, Iss. 1, pp. 50-50
Open Access | Times Cited: 158
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Otto Metzger, Giuseppe Viale, Shayna Stein, et al.
Cancer Discovery (2021) Vol. 11, Iss. 10, pp. 2474-2487
Open Access | Times Cited: 158
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
Zuzana Kos, Elvire Roblin, Rim S. Kim, et al.
npj Breast Cancer (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 152
Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up
Sabrina Kahler Ribeiro Fontana, Eleonora Pagan, Francesca Magnoni, et al.
European Journal of Surgical Oncology (2020) Vol. 47, Iss. 4, pp. 804-812
Closed Access | Times Cited: 145
Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer
Miquel Ensenyat-Méndez, Pere Llinàs‐Arias, Javier I. J. Orozco, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 119
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer
Michael Gnant, Florian Fitzal, Gabriel Rinnerthaler, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 5, pp. 395-405
Open Access | Times Cited: 118
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
Raz Mutai, Tamar Barkan, Assaf Moore, et al.
The Breast (2021) Vol. 60, pp. 62-69
Open Access | Times Cited: 115
St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer
Christoph Thomssen, Marija Balić, Nadia Harbeck, et al.
Breast Care (2021) Vol. 16, Iss. 2, pp. 135-143
Open Access | Times Cited: 111
Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes
Nasim Mavaddat, Leila Dorling, Sara Carvalho, et al.
JAMA Oncology (2022) Vol. 8, Iss. 3, pp. e216744-e216744
Open Access | Times Cited: 86
Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Jens Huober, Carlos H. Barrios, Naoki Niikura, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 25, pp. 2946-2956
Open Access | Times Cited: 79
Towards targeting the breast cancer immune microenvironment
Michael A. Harris, Peter Savas, Balaji Virassamy, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 8, pp. 554-577
Closed Access | Times Cited: 49
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
Lajos Pusztai, Carsten Denkert, Joyce O’Shaughnessy, et al.
Annals of Oncology (2024) Vol. 35, Iss. 5, pp. 429-436
Closed Access | Times Cited: 40
Page 1 - Next Page

Scroll to top